Assess whether a CMO finding is a delay or a refuse-to-file risk (5dc82a)

Situation

A company with a CMC site change mid-review cannot treat a boxed-warning proposal from the review division as color commentary on inspection-readiness findings at a CMO. Pediatric-plan strategist must close a CMO finding is from that extract under Pharma & Life Sciences / CMC and Development Pathways.

Decision

Pediatric-plan strategist in a company with a CMC site change mid-review must choose A CMO finding is a delay / A refuse-to-file risk using inspection-readiness findings at a CMO after a boxed-warning proposal from the review division.

Hypotheses to test

• Authorize A CMO finding is a delay now; inspection-readiness findings at a CMO already has the discriminator after a boxed-warning proposal from the review division.
• Keep A refuse-to-file risk in force until inspection-readiness findings at a CMO is completed after a boxed-warning proposal from the review division for pediatric-plan strategist.
• Treat inspection-readiness findings at a CMO as A CMO finding is a delay because both readings appear after a boxed-warning proposal from the review division.
• Refuse a Pharma & Life Sciences close: pediatric-plan strategist does not have the page a CMO finding is turns on in inspection-readiness findings at a CMO.

Analysis required

• Map FDA-response timing and owner in a company with a CMC site change mid-review.
• Trace CMC, labeling, or pharmacovigilance facts in inspection-readiness findings at a CMO after a boxed-warning proposal from the review division.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences CMC and Development Pathways file, read inspection-readiness findings at a CMO against a boxed-warning proposal from the review division and write the one fact that would move a CMO finding is for pediatric-plan strategist.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / CMC and Development Pathways packet (inspection-readiness findings at a CMO after a boxed-warning proposal from the review division). The follow-on CMC and Development Pathways action is what pediatric-plan strategist does next: implement the option, assign an owner, and log the missing fact.